Sanofi (SNY) Loses 9% as New Drug Candidate Appears Weaker Than Predecessor

We recently published 10 Major Stocks Collapse. Sanofi (NASDAQ:SNY) is one of the worst performers on Thursday.

Sanofi snapped a two-day winning streak on Thursday, shedding 9.14 percent to end at $45.33 apiece following the results of its drug candidate Amlitelimab that fell short of its predecessor’s benchmark.

In a statement, Sanofi (NASDAQ:SNY) said it was able to achieve its primary endpoints for its drug candidate, Amlitelimab, having demonstrated statistically significant and clinically meaningful skin clearance and disease severity compared to placebo at Week 24 in patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD).

It said that the drug candidate was well tolerated, without any safety concerns identified in the study.

However, Amlitelimab fell short of Dupixent’s benchmark, which, during its Phase 3 trial, already achieved promising results at Week 16, suggesting that it was way weaker than its predecessor.

According to Sanofi (NASDAQ:SNY), full results will be submitted for presentation at an upcoming medical meeting.

While we acknowledge the potential of SNY  as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.